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Abstract
Background: High-dose statins are used in acute coronary syndromes (ACS) to reduce
inflammation. The aim of the study was the evaluation of the influence of low-dose atorvastatin
(20 mg) on selected inflammatory parameters and clinical outcomes after ACS.
Methods: Seventy eight patients (pts) with ACS were randomly divided into group A (39 pts)
taking atorvastatin, and group NA (39 pts) not taking any statin for the following six weeks.
C-reactive protein (CRP), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1)
and tumour necrosis factor alpha (TNFa) levels were measured on the first and the fifth days
and six weeks after ACS.
Results: There was no significant CRP and IL-6 level decrease in group A (CRP — 62%;
IL-6 — 73%) or group NA (CRP — 44%; IL-6 — 62%). There was also no significant change
in TNFa levels. The MCP-1 level finally reached the level of significant difference (p < 0.04).
Cardiovascular events (MACE) and the restenosis rates did not differ between the groups.
Conclusions: Low-dose atorvastatin does not have a significant influence on cooling down
inflammation in ACS, and MCP-1 can be used as an early indicator of statin anti-inflamma-
tory activity. Furthermore, it does not reduce MACE or restenosis rates despite its influence on
MCP-1 levels. (Cardiol J 2008; 15: 357–364)
Key words: atorvastatin, acute coronary syndrome, inflammation, CRP, IL-6,
MCP-1, TNFa, restenosis
Introduction
Inflammation, statins and
acute coronary syndromes
One of most significant causes of plaque beco-
ming “vulnerable” and the natural progression of
the disease accelerating is the inflammatory state.
Many publications, as well as clinical studies, have
proven that increased levels of inflammatory mar-
kers are observed during acute coronary syndrome
(ACS); moreover, this finding has been demonstra-
ted to have a negative prognostic value.
C-reactive protein (CRP, measured using hi-
ghly sensitive methods — hsCRP) is used as
a predicative marker of clinical events (mostly
cardiovascular). Various statins have the poten-
tial to lower the CRP, either related or not rela-
ted to dose [1–4].
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The only completed randomized trial in which
interleukin 6 (IL-6) level profiles were assessed
during ACS was the Myocardial Ischemia Reduc-
tion with Aggressive Cholesterol Lowering
(MIRACL) study. The authors suggested the reason
for the lack of IL-6 reduction with atorvastatin use,
despite CRP and SAA (serum amyloid A) reduction,
might be the high diurnal variability, short half-life
(2–4 h compared to 20 h for CRP) and/or very low
serum concentration of this cytokine (about one tho-
usand times lower than CRP) [5].
There has been no large study regarding the
influence of statins administered during ACS on the
tumour necrosis factor alpha (TNFa) level. Patients
with a history of myocardial infarction had signifi-
cantly higher levels of this cytokine compared to
patients without infarction. Balbay et al. [6], in con-
trast, did not observe any difference in TNFa be-
tween stable and unstable patients.
Monocyte chemoattractant protein-1 (MCP-1)
plays a direct role in facilitating monocytes to per-
meate into the atherosclerotic plaque (mostly thro-
ugh “rolling”) as well as stimulating the inflamma-
tory state and transforming monocytes into “foam
cells” in the stable period of the disease. A relation-
ship between intensified MCP-1 expression and
rise of CPR activity has been observed, also du-
ring ACS [7]. It has been ascertained that the MCP-1
level is higher during ACS than stable coronary ar-
tery disease [8].
In the latest data obtained from the ARMYDA-
-CAMs study, attenuation of post-angioplasty incre-
ase of other inflammatory marker (adhesion mole-
cules) levels was observed after 7-day pre-treat-
ment with 40 mg of atorvastatin per day.
The treatment strategy for patients with ACS
includes multidirectional striving for plaque stabili-
zation. This has been tried using HMG-CoA inhibi-
tors (statins) and their anti-inflammatory properties.
Most of the data on the modification of inflam-
mation during ACS are included in the two big “sta-
tin” clinical trials: PROVE IT–TIMI-22 (PRavasta-
tin and atOrVastatin Evaluation and Infection The-
rapy–Thrombolysis in Myocardial Infarction 22)
[9–11] and A to Z (Aggrastat to Zocor) [10, 12], along
with post hoc analyses. The outcomes of these ana-
lyses gave rise to the hope that statin anti-inflam-
matory activity would be able to neutralize the in-
dependent disadvantageous impact of increased le-
vels of CRP and also encourage further studies.
Inflammation and restenosis
The main reason for restenosis (especially after
stent implantation) is the activation of an inflammatory
state which induces neointimal hyperplasia [13, 14].
Certain data suggesting the main role of MCP-1 in
stimulating restenosis seems of particular interest.
Several authors reported a higher level of this chemo-
kine in patients with restenosis than in de novo athero-
sclerosis or in the absence of restenosis [14, 15]. Thus,
reducing the inflammatory mediator level should
help achieve a reduction of the restenosis rate.
PROVE IT–TIMI 22 demonstrated that the
best clinical outcomes occur in patients who had
achieved very low (< 100 mg/dL or even < 70 mg/dL)
LDL serum concentrations and CRP levels (< 2 mg/dL).
However, these data, as well as others, revealed the
anti-inflammatory activity of high-dose statin tre-
atment (80 mg atorvastatin per day) during and after
ACS. The lowest dose of atorvastatin that is effec-
tive in lowering CRP levels in ACS on 30-day fol-
low-up is at present 40 mg [16]. Most physicians
(according to data obtained from EUROASPIRE
I and II survey [17]) do not use extremely high do-
ses of statins, for many reasons. The purpose of our
study was to determine whether a low dose of ato-
rvastatin causes a lowering of inflammatory mar-
kers during the 6 week period after ACS.
Methods
Patients
The study group consisted of 78 patients with
every kind of ACS included for study from 2003 until
2005. The diagnosis of ACS was based on the GRACE
criteria published in May 2002. Patients older than
75 years old, with LDL levels > 130 mg/dL, diabe-
tes, creatinine level > 2 mg/dL, liver dysfunction,
hyper- or hypothyreosis, a chronic inflammatory
state, or those undergoing treatment with steroids,
non-steroid anti-inflammatory drugs or statins
(in the month preceding ACS) were excluded. Hy-
pertension was diagnosed previously and was one
of the pre-existing conditions or was diagnosed ba-
sed on the JNC-7. Lipid ranges were accepted from
the NCEP ATP III guidelines. Every patient under-
went urgent coronary angiography, and afterwards
they were qualified to receive proper treatment.
They were randomly divided into two groups, either
taking or not taking atorvastatin at a dose of 20 mg
per day. In this way, the groups (A — patients ta-
king atorvastatin, NA — patients not taking any
statin) consisted of 39 patients each. The patients
did not differ between groups A and NA in clinical
status, therapy or early outcome of treatment
(Table 1). Blood samples were taken from the pa-
tients enrolled for the study on the first and fifth
days of ACS and after 6 weeks (to measure hsCRP,
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IL-6, TNFa, MCP-1, lipids and aminotransferases).
After 6 weeks most patients (35 patients, 89%) from
the NA group commenced treatment with atorva-
statin (20–40 mg/day) and all of the A group conti-
nued therapy with atorvastatin at a modified dose
(20–40 mg/day).
The study was approved by the local Bioethi-
cal Committee and all patients gave their informed
consent.
Clinical follow-up
Clinical follow-up was performed in all 78 pa-
tients (100%). The mean period of observation was
15.8 months (±SE = 0.89).
Angiographic follow-up
Angiographic follow-up was carried out at le-
ast 6 months after ACS in 68 (87%) patients. Sixty
two of them were treated during ACS with primary
percutaneous coronary intervention (PCI) with no
difference between the A and NA groups. The rest
of the investigated population did not agree to un-
dergo repeated angiography. Restenosis was identi-
fied when 50% of the coronary lumen diameter was
narrowed in the vessel previously treated with PCI.
Statistical analysis
Due to the lack of a normal distribution of data
confirmed in the Shapiro-Wilk test, in most cases
we used non-parametric methods for comparing
particular values. Mean values were compared
using the Mann-Whitney U-test. In the case of com-
paring variables for recurrent parameters, we used
Wilcoxon’s test for paired variables. Quality varia-
bles were examined in independent tests for mul-
ti-divided scoreboards: c2 Pearson test (in the case
of a low expected number we used the Yates’ update)
and, in the case of a general number lower than
40 for 2 × 2 scoreboards 0151, the exact Fisher’s
test. A statistical significance level of p = 0.05 was
accepted.
Results
Lipid and blood pressure measurements
Initially there were no significant differences
in lipids between the A and NA groups. Significant
differences between the A and NA groups were
observed after 6 weeks in total cholesterol,
LDL-cholesterol (p < 0.01) and triglyceride levels.
After 6 weeks the therapeutic goal (LDL level below
Table 1. Clinical characteristics of the group.
Whole group Atorvastatin group Non-atorvastatin group
N 78 39 39
Female 12 (15.4%) 6 (15.4%) 6 (15.4%)
Male 66 (84.6%) 33 (84.6%) 33 (84.6%)
STEMI 62 (79.5%) 32 (82.1%) 30 (76.9%)
NSTEMI 12 (15.4%) 4 (10.3%) 8 (20.5%)
UA 4 (5.1%) 3 (7.7%) 1 (2.6%)
Follow-up (x ± SE; months) 15.8±0.89 15.4±1.29 16.3±1.24
Age (x ± SE; years) 55±1.03 54±1.42 55±1.51
Primary PCI 71 (91.0%) 36 (92.3%) 35 (89.8%)
Smokers 58 (74.4%) 27 (69.2%) 31 (79.5%)
SBP (x ± SE; mm Hg) 147±7.7 146±6.8 148±5.6
DBP(x ± SE; mm Hg) 87±5.1 85±5.2 88±5.1
Hypertension 40 (51.2%) 23 (59.0%) 17 (43.6%)
Prior myocardial infarction 7 (9.0%) 4 (10.3%) 3 (7.7%)
Coronary disease de novo 62 (79.5%) 33 (84.6%) 29 (74.4%)
Acetylsalicylic acid 77 (98.7%) 39 (100%) 38 (97.4%)
Clopidogrel 70 (89.7%) 35 (89.7%) 35 (89.7%)
Abciximab 15 (19.2%) 8 (20.5%) 7 (17.9%)
CK-MB max (x ± SE; u/L) 217±20.01 211±29.8 223±27.01
LVEF (%); during ACS 46±1.02 46±1.66 46±1.24
p = NS (atorvastatin vs. non-atorvastatin group), PCI — percutaneous coronary intervention, ACS — acute coronary syndrome, UA — unstable angina,
NSTEMI — non-ST elevation myocardial infarction, STEMI — ST elevation myocardial infarction, NSTACS — non-ST elevation acute coronary syndrome
(= NSTEMI + UA), x — mean value, SE — standard error, LVEF — left ventricle ejection fraction, SBP — systolic blood pressure, DBP — diastolic
blood pressure
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100 mg/dL) was achieved in 31 patients (79.5%)
from the A group and in 7 patients (17.9%) from the
NA group (p < 0.01). The influence on the HDL-
-cholesterol level was not significant. In group A
there was a significant 13% reduction of total cho-
lesterol level, a 24% reduction of LDL-cholesterol
level after 6 weeks of treatment with atorvastatin
and an insignificant 5% increase of HDL-choleste-
rol level. In group NA there was a 23% increase of
LDL-cholesterol level and 5% decrease of HDL-
-cholesterol level. The triglyceride level increased
only by 5% in group A but by 20% in group NA.
These were non-significant changes, but after
6 weeks the difference between the investigated
groups was significant (Table 2).
The blood pressure did not differ between the
investigated groups throughout the study (p = NS).
After 6 weeks of the study the systolic blood pres-
sure was 137 ± 5.8 mm Hg (group A) and 138 ±
± 5.7 mm Hg (group NA).
Level of inflammatory markers
The levels of particular inflammatory markers
and their changes in the subgroups are shown in
Table 3 and Figures 1–3.
Table 3. Level of inflammatory markers.
A (n = 39) NA (n = 39) p
x±SE x±SE
CRP [mg/L] 10.06±3.5 10.55±3.25 < 0.03
— 1 day
CRP [mg/L] 18.81±4.4 19.01±2.96 NS
— 5 day
CRP [mg/L] 3.95±0.66 5.90±0.76 < 0.02
— 6 weeks
IL-6 [pg/mL] 10.07±2.0 9.72±1.95 NS
— 1 day
IL-6 [pg/mL] 7.27±1.45 7.04±1.03 NS
— 5 day
IL-6 [pg/mL] 2.65±0.34 3.69±0.86 NS
— 6 weeks
TNFa [pg/mL] 3.61±0.46 4.09±0.72 NS
— 1 day
TNFa [pg/mL] 4.18±0.48 5.01±0.68 NS
— 5 day
TNFa [pg/mL] 4.89±0.78 5.07±0.66 NS
— 6 weeks
MCP-1 [pg/mL] 363±29.93 315±20.99 NS
— 1 day
MCP-1 [pg/mL] 313±17.26 329±24.70 NS
— 5 day
MCP-1 [pg/mL] 361±20.16 422±23.60 < 0.04
— 6 weeks
x – mean value, SE – standard error;  p (A vs. NA), A — atorvastatin
group, NA — non-atorvastatin group
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(7.42 pg/mL) IL-6 reduction in group A and 62%
(6.03 pg/mL) reduction in group NA (a 28% diffe-
rence between the A and NA groups). In both ca-
ses the difference was visible but not statistically
significant. After 6 weeks there was a 35% incre-
ase of the TNFa level in group A and 24% increase
in group NA (p = NS). There was almost no chan-
ge in the MCP-1 level in group A (2 pg/mL) and
a 34% (107 pg/mL) increase in group NA. The dif-
ference between groups A and NA reached 17% and
was statistically significant (p < 0.04). Thus, after
6 weeks a significant influence on MCP-1 was ob-
served and this effect (although not originally signi-
ficant) was observed since the fifth day of ACS.
Clinical follow-up
There was no death in the investigated popu-
lation during follow-up. 11 (14.1%) major adverse
cardiovascular events (MACE, i.e.: ACS, stroke,
other significant vascular complications) were ob-
served in the entire group. The total number of ACS
was 7 (group A — 4, group NA — 3) in the entire
examined population.  There were no significant
differences between groups A and NA concerning
MACEs during the follow-up. There was no myopa-
thy, rhabdomyolysis or liver dysfunction (amino-
transferase increase) observed in either group.
Angiographic follow-up
Significant restenosis was observed in 18 pa-
tients (29%) who were treated with PCI and accep-
ted repeated angiography. There were no signifi-
cant differences between groups A (8 patients, 25%)
Initially there was a significant difference in the
CRP levels (p < 0.03) between groups A and NA.
There were no significant differences regading IL-6,
TNFa or MCP-1 levels. On the fifth day there were
still no significant differences between the groups.
After 6 weeks there was a 62% (6.24 mg/L) CRP
reduction in group A and 44% (4.65 mg/L) reduc-
tion in group NA (a 33% difference between the
A and NA groups). Similarly, there was a 73%
Figure 2. Changes of C-reactive protein (CRP) level;
A — atorvastatin group, NA — non-atorvastatin group.
Figure 3. Changes of monocyte chemoattractant prote-
in-1 (MCP-1) level; A — atorvastatin group, NA — non-
-atorvastatin group.
Figure 1. C-reactive protein (CRP) level decrease during
6 weeks (atorvastatin group [A] and non-atorvastatin
group [NA]); p (A vs. NA); DCRP 1 d. – 6 w. — CRP
decrease between 1 day and 6 week after ACS (A — 62%,
NA — 44%); DCRP 5. d. – 6. w. — CRP decrease betwe-
en 5 days and 6 weeks after ACS (A — 75%, NA — 70%).
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and NA (10 patients, 33%) although restenosis was
observed a little  more frequently in patients who did
not take any statin during the first 6 weeks after ACS.
Discussion
We observed a significant reduction in the to-
tal cholesterol and LDL-cholesterol levels in gro-
up A. This is consistent with a moderate dose, and
the 24% reduction of the LDL-cholesterol level is
less than reported in trials with high-dose atorva-
statin treatment. In PROVE IT (80 mg atorvastatin
per day) there was a 51% LDL-cholesterol level
reduction and in MIRACL (also 80 mg atorvastatin
per day) there was a 40% LDL-cholesterol level
reduction. It is comparable to the reduction in the
LDL-cholesterol level obtained with 40 mg per day
of pravastatin (PROVE IT 22%, REVERSAL trial
26%) [9]. The influence on the HDL-cholesterol
level is basically consistent with data obtained from
multicentre trials with atorvastatin (2% MIRACL
study, 6.5% PROVE IT study). The triglyceride
level change was not significant throughout our stu-
dy, which was also the case in the multicentre trials.
On the basis of the obtained results, we can say
that early usage of low-dose atorvastatin apparen-
tly caused the limited CRP increase after the onset
ACS, but it did not achieve a statistically significant
reduction. The CRP level obtained was compara-
ble with levels observed in earlier published trials.
When analyzing CRP changes over time (Fig. 1, 2)
there appears to be a characteristic curve to the
CRP level which exemplifies a “natural” course of
inflammation (group NA) compared to the “modi-
fied” course found with statin therapy (group A).
The first analysis of the effects of atorvastatin usa-
ge during ACS in a randomized, multicentre trial
was in the MIRACL study [5]. After 16 weeks of
treatment with 80 mg of atorvastatin and 40 mg of
pravastatin there was a 30% difference between the
groups, and at the end of follow-up (2.5 years) a 38%
difference between the CRP levels was observed
(p < 0.001). In the A to Z trial the significant CRP
level reduction occurred in the subgroup with ag-
gressive statin treatment (80 mg vs. 20 mg simva-
statin per day; p < 0.001). The difference between
the groups was 17%. It is vital to point out two diffe-
rences between these two big trials. In PROVE IT
the CRP level difference in the investigated groups
was 38% and in A to Z only 17%. In our own stu-
dy the difference achieved was 33% (but it was
not statistically significant). In the A to Z trial the
CRP level did not decrease until after 4 months of
treatment with simvastatin, and even then with
a maximal dose. In our own study this effect could
be seen earlier (after 6 weeks) but was not statisti-
cally significant. As mentioned above, the lowest
dose of atorvastatin that was efficient in lowering
CRP levels in ACS in 30-day follow-up, for the time
being, is 40 mg [16].
Despite the fact that a reasonably marked di-
stinction between IL-6 levels in groups A and NA
in our own study was indeed observed (28% after
6 weeks), it was not significant. A stable decreasing
trend of the IL-6 level (measured on the first and
fifth days and six weeks after ACS) may testify that
the peak level is before the fifth day of ACS and then
lowers rapidly until it reaches a point lower than at
the start of observation. This might be due to the
relatively short half-life of the cytokine. Similar
conclusions were reached in the MIRACL, in which,
after 16 weeks, there was no significant reduction
of IL-6 concentration in any of the subgroups [5].
Interesting facts regarding these findings may be
brought to light when FACS trial is completed [18].
Although, during the entire time of observa-
tion, TNFa levels were lower in group A (treated
with atorvastatin) than in group NA (without any
statin in treatment), there is an observable, conti-
nuously growing tendency in both groups, and the
increase in the level was higher (although not si-
gnificantly) in the group treated with atorvastatin
than in the group with no statin therapy. Brueck-
mann [19] noticed that the TNFa level was still
elevated 120 days after ACS. In contrast, Fahim et
al. [20] did not observe a higher TNFa level 48 ho-
urs after ACS. In Halawa’s study, observations [21]
showed a transient peak of this cytokine on the third
day after myocardial infarction. Balbay et al. [22],
in turn, did not report any differences between the
TNFa levels in patients with stable coronary arte-
ry disease or with infarction. Vasa et al. [23] publi-
shed an article in which they observed no signifi-
cant influence of atorvastatin on the level of this
inflammatory marker, which is similar to what we
formally report in this study. In summary, it can only
fairly be said that to date the obtained data are still
ambiguous and discrepant, and attempts at expla-
ining the reasons for this state of affairs (i.e., low
serum concentrations, putatively short half-life and
the involvement of many pathologic processes) are
essentially incomplete and need clarification by fur-
ther investigation.
Comparing MCP-1 levels (Fig. 3), there was
a significant difference between the groups after
6 weeks of follow-up (p = 0.038), ultimately re-
aching 61 pg/mL (17%). This marker was not ana-
lysed in any of the main randomized trials concer-
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ning ACS. In the study by Mazzone et al. [8] the
MCP-1 mean level measured in 29 patients during
the first hours of unstable angina was 267 pg/mL.
Kobusiak-Prokopowicz et al. [24] observed changes
of MCP-1 concentration in the acute phase of
ST-elevation myocardial infarction (STEMI). By
comparing these results to our own results, it can
be ascertained that the initial peak of MCP-1 (ob-
served in the mentioned study 3 hours after my-
ocardial pain started) was not directly detected in
our investigation. A possible reason for this is the
fact that we took blood samples only once during
the first day of ACS. However, the significant dif-
ference between the A and NA groups after 6 we-
eks of observation should be linked with the anti-
inflammatory activity of atorvastatin. Such activity
has also been described by other authors [25]. It
may be (concerning such changes of inflammatory
markers) that MCP-1 can be used as an earlier and
more efficient indicator than CRP and IL-6 of low-
dose statin anti-inflammatory activity during ACS.
The most recent data [26] suggest that also
other molecules, such as ICAM-1 and E-selectin,
may be influenced by atorvastatin earlier, and more
significantly, than CRP. The mentioned study was
conducted on a group of 76 patients with stable an-
gina, and it was observed that the CRP level did not
change significantly despite the use of atorvastatin,
whilst attenuation of post-PCI increase of adhesion
molecule levels was observed.
Extensive clinical studies have shown [5, 9, 10]
some clinical benefit (reduction of MACEs) in pa-
tients treated with a high dose of statins (simvasta-
tin, atorvastatin) during and after ACS. In our gro-
up we did not observe a significant reduction of
adverse events during clinical follow-up. These data
are consistent with the rather surprising results of
the last large meta-analysis concerning the role of
statin therapy in ACS [27].
Because we observed a significant influence on
MCP-1 levels in the group treated with atorvasta-
tin, we continued our investigation in order to de-
termine whether there was a significant relation-
ship with the reduction of the restenosis rate. At
present there is no oral treatment available which
is able to reduce both inflammation (especially
MCP-1) and restenosis after stent implantation.
Unfortunately, we observed only a non-significant
trend in reducing restenosis rates in group A (25%
vs. 33.3% in group NA; p = NS), despite a signifi-
cant influence on MCP-1 levels. Perhaps higher
doses of atorvastatin could yet play a positive role
in reducing the restenosis rate, although there are
as yet no reliable data to support this hypothesis.
Limitations of the study
The significance of some of our results could
be limited by the small number of patients in the
investigated groups as well as the relatively short
period of follow-up. Another limitation is that pa-
tients from the non-atorvastatin group started to
take statins after 6 weeks of observation. This may
particularly limit the clinical outcome of the study,
which is why the conclusions are focused only on
inflammatory markers, although some clinical ob-
servations have been made. Of particular interest
is the observation that low-dose atorvastatin does
not significantly reduce the restenosis rate despite
its influence on the MCP-1 level.
Conclusions
In conclusion, we were able to ascertain that
low-dose atorvastatin produces a beneficial but
weak (not significant) influence on cooling down in-
flammation in ACS. MCP-1 may serve as an earlier
and more efficient indicator than CRP and IL-6 of low-
dose statin anti-inflammatory activity during ACS.
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